• FDA grants orphan drug designation for LHON gene therapy

    1 month ago - By Gene Therapy

    Posted on: 26 September 2020,
    Neurophth Therapeutics has received orphan drug designation from the FDA for NR082 for the treatment of Leber hereditary optic neuropathy associated with ND4 mutation, according to a press release. Between 70% and 90% of LHON cases are caused by ND4 mutation, according to the release.
    {fastsocialshare}
    {loadposition user9}
    Read more ...